Evidence map›Paper›PMID 36387537›Full record

ArticleHeliyon2022

Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases.

Jianwei Liu, Hui Xue, Shilei Bai, Jie Wang, Yue Zhang, Liu Liu, Lei Zhang, Zhao Yang, KuiWang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jianwei LiuDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Hui XueDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Shilei BaiDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Jie WangDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yue ZhangDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Liu LiuDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Lei ZhangDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Zhao YangDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
KuiWangDepartment of Hepatic Surgery Ⅱ, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the recent advances in immunotherapy, especially programmed cell death protein 1 (PD-1) inhibitors, the treatment of hepatocellular carcinoma (HCC) patients has entered a new stage. However, few reports have focused on spontaneous bacterial peritonitis (SBP) after PD-1 inhibitor treatment of intermediate-to advanced-stage HCC. In this article, we report two clinical cases of SBP after successful PD-1 inhibitor therapy. The patient's condition was assessed as a complete response (CR) according to the mRECIST criteria. Based on these two cases, we found that patients with large or giant HCC who have large tumour diameter should be closely monitored for SBP after successful PD-1 inhibitor therapy, especially when the imaging shows the rapid development of marked necrosis and depression at the tumour site. Early and active treatment is necessary to reduce the suffering caused by SBP.

Indexed as

ComplicationHepatocellular carcinomaProgrammed cell death protein 1Spontaneous peritonitisTreatment

Identifiers

PMID36387537
PMCPMC9649979
OpenAlexW4307727411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.